Afipia
Afipia[edit]
''Afipia felis'', the type species of the genus Afipia.
Afipia is a genus of Gram-negative bacteria that belongs to the family Alcaligenaceae. The genus was first described in 1987 by Brenner et al. and is named after the Armed Forces Institute of Pathology (AFIP) in the United States. The type species of the genus is Afipia felis.
Taxonomy[edit]
The genus Afipia is classified under the phylum Proteobacteria, class Betaproteobacteria, order Burkholderiales, and family Alcaligenaceae. It currently contains six recognized species:
1. Afipia felis 2. Afipia broomeae 3. Afipia clevelandensis 4. Afipia birgiae 5. Afipia massiliensis 6. Afipia septicemium
Morphology and Physiology[edit]
Afipia bacteria are small, rod-shaped organisms that are typically motile due to the presence of flagella. They are facultative anaerobes, meaning they can survive in both aerobic and anaerobic conditions. These bacteria are also oxidase-positive and catalase-positive.
Habitat and Distribution[edit]
Afipia bacteria are commonly found in aquatic environments, including freshwater and marine habitats. They have also been isolated from various animals, such as cats, dogs, and humans. Afipia felis is particularly associated with feline hosts and has been implicated in causing diseases in cats.
Pathogenicity[edit]
While some species of Afipia are considered opportunistic pathogens, their pathogenic potential is not well understood. Afipia felis has been associated with a range of clinical conditions in cats, including pneumonia, endocarditis, and lymphadenitis. However, further research is needed to fully understand the pathogenic mechanisms of Afipia bacteria.
Importance in Research[edit]
Afipia bacteria have attracted attention in research due to their unique characteristics and potential medical significance. They have been studied for their ability to survive and persist in diverse environments, including within host cells. Additionally, their interactions with the host immune system and potential role in disease development are areas of ongoing investigation.
References[edit]
<references />
See Also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends ✔ Tele visits available with certain limitations Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian